Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Aytu BioPharma reported fiscal Q4 2026 net revenue of $16.1 million, up 6.4% year over year, and adjusted EBITDA of $0.5 million. EXXUA generated $6.6 million of fiscal-year revenue, including $3.9 million in Q4 following its full commercial launch in Q3, while prescriptions rose 138% sequentially to 3,323. The company ended June with $26.3 million in cash, highlighting early commercial traction for EXXUA.

Analysis

AYTU’s investability now hinges on whether EXXUA demand converts from an early-launch prescription ramp into repeatable, low-cash-burn growth. The implied quarterly revenue per reported prescription is unusually high, making channel inventory build, gross-to-net deductions, prescription-duration definitions, and refill persistence more important than headline script growth. A clean reconciliation on the call could support a revenue-multiple rerating over 1-3 months; ambiguity would reinforce the market’s typical discount for micro-cap commercial launches.

The immediate earnings signal is less valuable than the next two quarters of prescription velocity and commercial expense discipline. With a limited absolute cash cushion for a branded CNS launch, sales-force expansion or payer-access spending that outpaces incremental gross profit would increase financing risk within 6-18 months. Conversely, sustained sequential script growth with stable cash usage would reduce dilution risk and demonstrate that the company can fund the launch internally.

Competitive risk is not simply other branded antidepressants: low-cost generic SSRIs/SNRIs create a high bar for formulary placement, while Axsome’s AUVELITY (AXSM) and Johnson & Johnson’s SPRAVATO (JNJ) set the branded-treatment benchmark for treatment-resistant populations. The contrarian view is that the market may be over-crediting an initial launch curve before persistence data emerge; early prescriber sampling and distributor stocking can create a sharp but non-linear deceleration after the first several quarters.

Key Decisions for Investors

• Maintain AYTU as a trading watch rather than a core long until the conference call provides quarterly new-versus-refill prescriptions, gross-to-net trends, inventory/channel commentary, and cash-burn guidance. Upgrade only if management demonstrates sequential prescription growth above 25% with no material acceleration in operating cash use over the next two reported quarters.
• For high-risk biotech sleeves, consider a small tactical AYTU long only after confirmation that Q4 revenue is predominantly end-demand rather than distributor stocking; target a 1-3 month catalyst window around the next prescription update. Size for binary liquidity risk and exit on a material guidance cut, equity raise, or sequential EXXUA prescription growth below 10%.
• Avoid using AXSM as a clean short hedge: AYTU’s commercial scale is too small to affect AXSM fundamentals. Instead, monitor AXSM payer-access commentary and branded antidepressant demand trends as external validation of whether EXXUA can sustain premium net pricing.
• Set an alert for cash falling below roughly $15 million or operating losses widening despite prescription growth; either development would materially raise the probability of dilutive financing and should override launch-momentum signals.